Plain-English translation of NCT05541601 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a long-term study designed to help doctors catch liver cancer earlier in people who have cirrhosis—severe scarring of the liver. Researchers will collect blood, urine, and imaging scans from 3,000 participants over four years to discover new biomarkers (signs in your blood) that can predict who is most likely to develop liver cancer and detect it at the earliest possible stage.
People with cirrhosis have a higher risk of developing liver cancer, but current screening methods sometimes miss early cases. This study aims to develop better, more accurate blood tests that could catch cancer sooner, when treatment is most likely to succeed.
You likely qualify if…
You likely don't qualify if…
You would visit the research clinic regularly over four years for blood and urine samples, ultrasound or CT scans, and other imaging tests. These visits help researchers track changes in your liver health and test new blood-based biomarkers for early cancer detection. The study is observational, meaning you are not taking a new medication—researchers are simply collecting samples and data to discover which tests work best at catching liver cancer early.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United Kingdom
Sponsor
University of Oxford
Collaborators
Cancer Research UK, Roche Diagnostic Ltd.
Enrollment target
~3,000 participants
Started
February 2022
Primary completion
July 2037
Age range
18 Years – 100 Years
Last updated on clinicaltrials.gov in September 2022.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Study Coordinator
University of Oxford
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.